Gilead Sciences Stock News

Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results, driving optimism for continued growth. Gilead Sciences key growth drivers, include robust sales from Livdelzi and Yeztugo, alongside patent protection for Biktarvy until 2036. Despite a higher P/FCF ratio, Gilead Sciences is still undervalued, with an intrinsic value estimate of $146.12, supporting its invest...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the...

Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch Yeztugo, is expected to sustain growth with no major patent expiries until 2036. While oncology / immunology remain weaker segments, recent strategic M&A like CymaBay and a new CMO with oncology experti...

Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the cheapest quality names using a Magic-Formula-style scoring method.

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.

Gilead Sciences, Inc. ( GILD ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Thanks so much for attending the Jefferies Healthcare -- London Healthcare Conference. It's already day 3.

FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV preve...

Amgen is performing well despite some headwinds, and its pipeline is progressing. Gilead Sciences' strong core franchise and diversification efforts should work wonders.